| Susan Bowers, | |
|
154 Saluda Pointe Ct., Lexington, SC 29072-2907 | |
| (803) 785-3590 | |
| Not Available |
| Full Name | Susan Bowers |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 154 Saluda Pointe Ct., Lexington, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629420286 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | APN.20173 APRN (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Home Health | Columbia, SC | Home health agency |
| Lexington Medical Center | West columbia, SC | Hospital |
| Kershawhealth | Camden, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lexington Health Inc | 2567872070 | 753 |
| Sc House Calls Inc | 6800994807 | 358 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
| Entity Name | Sc House Calls Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518048859 PECOS PAC ID: 6800994807 Enrollment ID: O20070613000821 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
| Entity Name | Kershaw Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316322027 PECOS PAC ID: 2668773698 Enrollment ID: O20151221002384 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
| Entity Name | App Of South Carolina Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457878084 PECOS PAC ID: 3577821107 Enrollment ID: O20180103000650 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
| Entity Name | Lexington Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710634753 PECOS PAC ID: 2567872070 Enrollment ID: O20201208000922 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
| Entity Name | Musc Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841878006 PECOS PAC ID: 6507260668 Enrollment ID: O20210811002388 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan Bowers, Po Box 6069, West Columbia, SC 29171-6069 Ph: (803) 791-2203 | Susan Bowers, 154 Saluda Pointe Ct., Lexington, SC 29072-2907 Ph: (803) 785-3590 |
News Archive
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.
There is a growing body of evidence revealing the connection between neglected tropical diseases (NTDs) and HIV/AIDS, prompting experts to call for greater integration of national NTD treatment programs with HIV/AIDS initiatives.
Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
› Verified 6 days ago
Victoria Fenters, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1316 N Lake Dr, Lexington, SC 29072 Phone: 803-358-1191 | |
Dr. Brooke Patterson, DNP, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 815 Old Cherokee Rd, Lexington, SC 29072 Phone: 803-359-5181 | |
Mrs. Carolyn Birchmore, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1316 N Lake Dr, Lexington, SC 29072 Phone: 803-358-1191 Fax: 803-358-1180 | |
Amy Loper, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 811 W Main St Ste 207, Lexington, SC 29072 Phone: 803-358-6420 | |
Mrs. Willetta Rozena Jacobs, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1847 S Lake Dr, Lexington, SC 29073 Phone: 803-356-8998 | |
Donna Marie Bridger, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2480 Two Notch Rd, Lexington, SC 29072 Phone: 803-951-5871 Fax: 803-951-5882 | |
Emilee Rikard Campbell, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 811 W Main St Ste 201&209, Lexington, SC 29072 Phone: 803-785-4777 Fax: 803-358-6240 |